Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T77365 | ||||
Target Name | Adenosine A2a receptor (ADORA2A) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Caffeine | Drug Info | IC50 = 17 nM | [59] | |
Apadenoson | Drug Info | Ki = 0.5 nM | [17] | ||
Istradefylline | Drug Info | Ki = 13 nM | [58] | ||
Tonapofylline | Drug Info | Ki = 29 nM | [17] | ||
(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl | Drug Info | Ki = 10500 nM | [43] | ||
(E,E)-8-(4-Phenylbutadien-1-yl)caffeine | Drug Info | Ki = 153 nM | [37] | ||
(E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine | Drug Info | Ki = 59.1 nM | [37] | ||
(E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine | Drug Info | Ki = 104 nM | [37] | ||
(E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine | Drug Info | Ki = 114 nM | [37] | ||
(S)-DHPA | Drug Info | Ki = 8500 nM | [39] | ||
(Z)-8-(3-chlorostyryl)caffeine | Drug Info | Ki = 30.2 nM | [37] | ||
1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 1400 nM | [53] | ||
1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 14000 nM | [50] | ||
1,3-Diallyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 820 nM | [51] | ||
1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 4000 nM | [53] | ||
1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 14000 nM | [53] | ||
1,3-Diethyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 1200 nM | [51] | ||
1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 1700 nM | [53] | ||
1,3-Dipropyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 680 nM | [51] | ||
1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 6500 nM | [53] | ||
1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 642 nM | [7] | ||
1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 5000 nM | [53] | ||
1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 2200 nM | [7] | ||
1-METHYLXANTHINE | Drug Info | Ki = 6600 nM | [51] | ||
1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea | Drug Info | Ki = 920 nM | [5] | ||
1H-Imidazo[4,5-c]quinolin-4-ylamine HCl | Drug Info | Ki = 1400 nM | [43] | ||
2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine | Drug Info | Ki = 2160 nM | [40] | ||
2,6,8-triphenyl-9H-purine | Drug Info | Ki = 66 nM | [18] | ||
2,6-diphenyl-1-deazapurine | Drug Info | Ki = 39 nM | [22] | ||
2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine | Drug Info | Ki = 247 nM | [22] | ||
2,6-diphenyl-8-ethyl-1-deazapurine | Drug Info | Ki = 177 nM | [22] | ||
2,6-diphenyl-8-methyl-1-deazapurine | Drug Info | Ki = 375 nM | [22] | ||
2,6-diphenyl-8-tButyl-1-deazapurine | Drug Info | Ki = 1055 nM | [22] | ||
2,6-diphenyl-9H-purine | Drug Info | Ki = 53 nM | [18] | ||
2,6-Diphenyl-pyrimidin-4-ylamine | Drug Info | Ki = 169 nM | [30] | ||
2,6-dphenyl-8-propyl-1-deazapurine | Drug Info | Ki = 114 nM | [22] | ||
2-(1H-benzo[d]imidazol-2-yl)quinoxaline | Drug Info | Ki = 561 nM | [32] | ||
2-(2''-indolylethyloxy)adenosine | Drug Info | Ki = 373 nM | [24] | ||
2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine | Drug Info | Ki = 2.9 nM | [29] | ||
2-(3''(5''-chloro-indolyl)ethyloxy)adenosine | Drug Info | Ki = 390 nM | [24] | ||
2-(3''(7''-bromo-indolyl)ethyloxy)adenosine | Drug Info | Ki = 252 nM | [24] | ||
2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine | Drug Info | Ki = 39.7 nM | [24] | ||
2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine | Drug Info | Ki = 502 nM | [24] | ||
2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine | Drug Info | Ki = 370 nM | [24] | ||
2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine | Drug Info | Ki = 450 nM | [24] | ||
2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine | Drug Info | Ki = 900 nM | [24] | ||
2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine | Drug Info | Ki = 1400 nM | [24] | ||
2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine | Drug Info | Ki = 150 nM | [24] | ||
2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine | Drug Info | Ki = 29.3 nM | [24] | ||
2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine | Drug Info | Ki = 3870 nM | [24] | ||
2-(3''-indolylethyloxy)adenosine | Drug Info | Ki = 45 nM | [24] | ||
2-(3''-pyrrolylethyloxy)adenosine | Drug Info | Ki = 95 nM | [24] | ||
2-(4-chlorophenyl)-6-phenyl-9H-purine | Drug Info | Ki = 315 nM | [18] | ||
2-(4-ethylthiobenzimidazol-2-yl)quinoxaline | Drug Info | Ki = 3440 nM | [16] | ||
2-(4-hydroxypent-1-yl)-N6-methoxyadenosine | Drug Info | Ki = 758 nM | [23] | ||
2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline | Drug Info | Ki = 833 nM | [32] | ||
2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine | Drug Info | Ki = 1820 nM | [23] | ||
2-(6-amino-8-bromo-9H-purin-9-yl)ethanol | Drug Info | Ki = 620 nM | [48] | ||
2-(hex-1-ynyl)-N6-methoxyadenosine | Drug Info | Ki = 267 nM | [23] | ||
2-Amino-4,6-di-furan-2-yl-nicotinonitrile | Drug Info | Ki = 1 nM | [36] | ||
2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile | Drug Info | Ki = 32 nM | [36] | ||
2-Amino-4,6-diphenyl-nicotinonitrile | Drug Info | Ki = 130 nM | [36] | ||
2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile | Drug Info | Ki = 22.7 nM | [30] | ||
2-Amino-4,6-diphenyl-pyrimidine | Drug Info | Ki = 405 nM | [30] | ||
2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile | Drug Info | Ki = 19 nM | [36] | ||
2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile | Drug Info | Ki = 88 nM | [36] | ||
2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile | Drug Info | Ki = 11 nM | [36] | ||
2-amino-6-phenyl-4-p-tolylnicotinonitrile | Drug Info | Ki = 118 nM | [19] | ||
2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile | Drug Info | Ki = 54 nM | [36] | ||
2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide | Drug Info | Ki = 17 nM | [35] | ||
2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 20 nM | [34] | ||
2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 391 nM | [34] | ||
2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine | Drug Info | Ki = 740 nM | [43] | ||
2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 30 nM | [34] | ||
2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 681 nM | [34] | ||
2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 13 nM | [34] | ||
2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 1.6 nM | [34] | ||
2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine | Drug Info | Ki = 69 nM | [34] | ||
2-ethynyl-N6-methoxyadenosine | Drug Info | Ki = 3140 nM | [23] | ||
2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine | Drug Info | Ki = 228 nM | [26] | ||
2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine | Drug Info | Ki = 329 nM | [26] | ||
2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine | Drug Info | Ki = 290 nM | [43] | ||
2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine | Drug Info | Ki = 91 nM | [26] | ||
2-phenylpropoxyadenosine | Drug Info | Ki = 500 nM | [24] | ||
2-tolyl-6-phenyl-9H-purine | Drug Info | Ki = 289 nM | [18] | ||
2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine | Drug Info | Ki = 2680 nM | [23] | ||
2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine | Drug Info | Ki = 3960 nM | [23] | ||
3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol | Drug Info | Ki = 3330 nM | [13] | ||
3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol | Drug Info | Ki = 9140 nM | [13] | ||
3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 6000 nM | [53] | ||
3-noradamantyl-1,3-dipropylxanthine | Drug Info | Ki = 673 nM | [20] | ||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | Ki < 1000 nM | [49] | ||
4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine | Drug Info | Ki = 5 nM | [19] | ||
4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine | Drug Info | Ki = 242 nM | [38] | ||
4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine | Drug Info | Ki = 14 nM | [35] | ||
4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine | Drug Info | Ki = 35 nM | [34] | ||
4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile | Drug Info | Ki = 19 nM | [30] | ||
5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol | Drug Info | Ki = 4920 nM | [31] | ||
5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol | Drug Info | Ki = 192 nM | [22] | ||
5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine | Drug Info | Ki = 5360 nM | [13] | ||
5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine | Drug Info | IC50 = 71 nM | [9] | ||
6-(furan-2-yl)-9H-purin-2-amine | Drug Info | Ki = 261 nM | [38] | ||
6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine | Drug Info | Ki = 270.5 nM | [11] | ||
6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine | Drug Info | Ki = 68.5 nM | [11] | ||
6-guanidino-2-(3''-indolylethyloxy)adenosine | Drug Info | Ki = 277 nM | [24] | ||
7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 10000 nM | [53] | ||
7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 700 nM | [53] | ||
7-Isopropyl-7H-adenine | Drug Info | Ki = 12000 nM | [39] | ||
7-Propyl-7H-adenine | Drug Info | Ki = 18000 nM | [39] | ||
8-Br-adenine | Drug Info | Ki = 3200 nM | [39] | ||
8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine | Drug Info | Ki = 4000 nM | [39] | ||
8-Bromo-9-(2-butyl)-9H-adenine | Drug Info | Ki = 730 nM | [39] | ||
8-Bromo-9-(2-hydroxypropyl)-9H-adenine | Drug Info | Ki = 1100 nM | [39] | ||
8-Bromo-9-(3-hydroxypropyl)-9H-adenine | Drug Info | Ki = 85 nM | [39] | ||
8-Bromo-9-(but-3-enyl)-9H-adenine | Drug Info | Ki = 1600 nM | [39] | ||
8-Bromo-9-(sec-butyl)-9H-adenine | Drug Info | Ki = 390 nM | [39] | ||
8-Bromo-9-cyclobutyl-9H-adenine | Drug Info | Ki = 660 nM | [39] | ||
8-Bromo-9-cyclohexyl-9H-adenine | Drug Info | Ki = 15000 nM | [39] | ||
8-Bromo-9-cyclopentyl-9H-adenine | Drug Info | Ki = 1900 nM | [39] | ||
8-Bromo-9-ethyl-9H-adenine | Drug Info | Ki = 52 nM | [39] | ||
8-bromo-9-isobutyl-9H-purin-6-amine | Drug Info | Ki = 6000 nM | [48] | ||
8-Bromo-9-isopropyl-9H-adenine | Drug Info | Ki = 74 nM | [39] | ||
8-Bromo-9-methyl-9H-adenine | Drug Info | Ki = 120 nM | [39] | ||
8-Bromo-9-phenylethyl-9H-adenine | Drug Info | Ki = 4900 nM | [39] | ||
8-Bromo-9-propyl-9H-adenine | Drug Info | Ki = 300 nM | [39] | ||
8-PHENYL THEOPHYLLINE | Drug Info | Ki = 850 nM | [43] | ||
8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 1900 nM | [7] | ||
8-propyl-2,6-diphenyl-9H-purine | Drug Info | Ki = 167 nM | [18] | ||
9-(2-Hydroxyethyl)-9H-adenine | Drug Info | Ki = 11000 nM | [39] | ||
9-(2-Hydroxypropyl)-9H-adenine | Drug Info | Ki = 3100 nM | [39] | ||
9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine | Drug Info | Ki = 23 nM | [35] | ||
9-(3-Hydroxypropyl)-9H-adenine | Drug Info | Ki = 3900 nM | [39] | ||
9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine | Drug Info | Ki = 85 nM | [35] | ||
9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine | Drug Info | Ki = 372 nM | [35] | ||
9-(sec-Butyl)-9H-adenine | Drug Info | Ki = 16000 nM | [39] | ||
9-Allyl-8-bromo-9H-adenine | Drug Info | Ki = 730 nM | [39] | ||
9-benzyl-6-(furan-2-yl)-9H-purin-2-amine | Drug Info | Ki = 40 nM | [35] | ||
9-Benzyl-8-bromo-9H-adenine | Drug Info | Ki = 6100 nM | [39] | ||
9-BENZYL-9H-ADENINE | Drug Info | Ki = 8500 nM | [39] | ||
9-But-3-enyl-9H-adenine | Drug Info | Ki = 8500 nM | [39] | ||
9-Butyl-9H-adenine | Drug Info | Ki = 7800 nM | [39] | ||
9-Cyclobutyl-9H-adenine | Drug Info | Ki = 4800 nM | [39] | ||
9-Cycloheptyl-9H-adenine | Drug Info | Ki = 11000 nM | [39] | ||
9-Cyclopentyl-9H-adenine | Drug Info | Ki = 1800 nM | [39] | ||
9-Cyclopropyl-9H-adenine | Drug Info | Ki = 2300 nM | [39] | ||
9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine | Drug Info | Ki = 600 nM | [6] | ||
9-Ethyl-9H-adenine | Drug Info | Ki = 2200 nM | [39] | ||
9-Isopropyl-9H-adenine | Drug Info | Ki = 4100 nM | [39] | ||
9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine | Drug Info | Ki = 46.3 nM | [15] | ||
9-Methyl-9H-adenine | Drug Info | Ki = 6900 nM | [39] | ||
9-Phenylethyl-9H-adenine | Drug Info | Ki = 9600 nM | [39] | ||
9-Propyl-9H-adenine | Drug Info | Ki = 9600 nM | [39] | ||
Alloxazine | Drug Info | Ki = 935 nM | [15] | ||
ARISTEROMYCIN | Drug Info | Ki = 2150 nM | [3] | ||
CVT-6883 | Drug Info | Ki = 3280 nM | [41] | ||
Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine | Drug Info | Ki = 16000 nM | [12] | ||
Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine | Drug Info | Ki = 14000 nM | [12] | ||
Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate | Drug Info | Ki = 1640 nM | [47] | ||
FK-453 | Drug Info | IC50 = 1180 nM | [47] | ||
FK-838 | Drug Info | Ki = 1202 nM | [47] | ||
FR-166124 | Drug Info | IC50 = 6200 nM | [1] | ||
Galangin | Drug Info | Ki = 18100 nM | [55] | ||
GNF-PF-2224 | Drug Info | Ki = 157 nM | [45] | ||
GNF-PF-2700 | Drug Info | Ki = 624 nM | [48] | ||
GW-328267 | Drug Info | IC50 = 0.4 nM | [44] | ||
isobutylmethylxanthine | Drug Info | Ki = 8000 nM | [53] | ||
Isoguanosine | Drug Info | Ki = 331 nM | |||
Istradefylline | Drug Info | Ki = 2 nM | [29] | ||
KF-17837 | Drug Info | Ki = 1 nM | [54] | ||
Kuanoniamine D | Drug Info | Ki = 13700 nM | [56] | ||
LUF-5417 | Drug Info | Ki = 2340 nM | [47] | ||
LUF-5433 | Drug Info | Ki = 1900 nM | [47] | ||
LUF-5437 | Drug Info | Ki = 570 nM | [5] | ||
LUF-5767 | Drug Info | Ki = 899 nM | [10] | ||
LUF-5956 | Drug Info | Ki = 148 nM | [18] | ||
LUF-5957 | Drug Info | Ki = 118 nM | [18] | ||
LUF-5962 | Drug Info | Ki = 55 nM | [18] | ||
LUF-5978 | Drug Info | Ki = 189 nM | [22] | ||
LUF-5980 | Drug Info | Ki = 230 nM | [22] | ||
LUF-5981 | Drug Info | Ki = 194 nM | [22] | ||
METHYLTHIOADENOSINE | Drug Info | Ki = 1180 nM | [8] | ||
METRIFUDIL | Drug Info | Ki = 25 nM | [2] | ||
N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine | Drug Info | Ki = 1700 nM | [12] | ||
N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide | Drug Info | Ki = 381 nM | [10] | ||
N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide | Drug Info | Ki = 157 nM | [10] | ||
N-(2,6-diphenylpyrimidin-4-yl)acetamide | Drug Info | Ki = 489 nM | [10] | ||
N-(2,6-diphenylpyrimidin-4-yl)butyramide | Drug Info | Ki = 124 nM | [10] | ||
N-(2,6-diphenylpyrimidin-4-yl)isobutyramide | Drug Info | Ki = 376 nM | [10] | ||
N-(2,6-diphenylpyrimidin-4-yl)propionamide | Drug Info | Ki = 81.9 nM | [10] | ||
N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide | Drug Info | Ki = 209 nM | [46] | ||
N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide | Drug Info | Ki = 4400 nM | [5] | ||
N-(4,6-diphenylpyrimidin-2-yl)propionamide | Drug Info | Ki = 893 nM | [10] | ||
N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide | Drug Info | Ki = 8700 nM | [5] | ||
N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide | Drug Info | Ki = 3030 nM | [47] | ||
N6-((+/-)-endo-norborn-2-yl)adenosine | Drug Info | Ki = 1270 nM | [40] | ||
N6-(4-hydroxybenzyl)adenine riboside | Drug Info | Ki = 2620 nM | [25] | ||
N6-CYCLOPENTYLADENOSINE | Drug Info | Ki = 2470 nM | [47] | ||
N6-methoxy-2-phenylethynyladenosine | Drug Info | Ki = 4290 nM | [23] | ||
N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine | Drug Info | Ki = 2960 nM | [23] | ||
N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine | Drug Info | Ki = 12500 nM | [23] | ||
N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine | Drug Info | Ki = 1780 nM | [23] | ||
N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine | Drug Info | Ki = 6520 nM | [23] | ||
N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine | Drug Info | Ki = 6310 nM | [23] | ||
N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine | Drug Info | Ki = 5740 nM | [23] | ||
N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine | Drug Info | Ki = 4170 nM | [28] | ||
N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine | Drug Info | Ki = 1900 nM | [28] | ||
PD-115199 | Drug Info | Ki = 15.5 nM | [14] | ||
Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol | Drug Info | Ki = 9524 nM | [33] | ||
PSB-0788 | Drug Info | Ki = 1730 nM | [41] | ||
PSB-09120 | Drug Info | Ki = 122 nM | [41] | ||
PSB-601 | Drug Info | Ki = 93.7 nM | [41] | ||
R-N6-(phenylisopropyl)adenosine | Drug Info | Ki = 884 nM | [24] | ||
SB-298 | Drug Info | Ki = 2139 nM | [41] | ||
SCH 420814 | Drug Info | Ki = 0.6 nM | [21] | ||
SCH-442416 | Drug Info | Ki = 0.5 nM | [4] | ||
SCH-63390 | Drug Info | Ki = 2.4 nM | [57] | ||
ST-1535 | Drug Info | Ki = 6.6 nM | [36] | ||
Tonapofylline | Drug Info | Ki = 2440 nM | [47] | ||
ZM-241385 | Drug Info | Ki = 1.2 nM | [42] | ||
[3H]CCPA | Drug Info | Ki = 2300 nM | [27] | ||
[3H]NECA | Drug Info | Ki = 22 nM | [52] | ||
[3H]OSIP339391 | Drug Info | Ki = 328 nM | [48] | ||
References | |||||
REF 1 | Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1979-84. | ||||
REF 2 | N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 1999 Sep 9;42(18):3463-77. | ||||
REF 3 | Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem. 2000 Jun 1;43(11):2196-203. | ||||
REF 4 | Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62. | ||||
REF 5 | Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62. | ||||
REF 6 | Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4. | ||||
REF 7 | Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. | ||||
REF 8 | Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55. | ||||
REF 9 | Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6. | ||||
REF 10 | 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. | ||||
REF 11 | 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2119-22. | ||||
REF 12 | Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. | ||||
REF 13 | 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10. | ||||
REF 14 | (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5. | ||||
REF 15 | 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. | ||||
REF 16 | 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. | ||||
REF 17 | Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64. | ||||
REF 18 | 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. | ||||
REF 19 | Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7. | ||||
REF 20 | Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. | ||||
REF 21 | Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimid... Bioorg Med Chem Lett. 2007 Mar 1;17(5):1376-80. | ||||
REF 22 | 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. | ||||
REF 23 | N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. | ||||
REF 24 | Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. | ||||
REF 25 | Neuroprotective principles from Gastrodia elata. J Nat Prod. 2007 Apr;70(4):571-4. | ||||
REF 26 | New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. | ||||
REF 27 | 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. | ||||
REF 28 | N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47. | ||||
REF 29 | Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. J Med Chem. 2008 Feb 14;51(3):400-6. | ||||
REF 30 | A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. | ||||
REF 31 | Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. | ||||
REF 32 | Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. | ||||
REF 33 | Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. | ||||
REF 34 | Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. | ||||
REF 35 | Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. | ||||
REF 36 | 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. | ||||
REF 37 | Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. | ||||
REF 38 | Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47. | ||||
REF 39 | 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. | ||||
REF 40 | N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. | ||||
REF 41 | 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. | ||||
REF 42 | 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52. | ||||
REF 43 | 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. | ||||
REF 44 | Synthesis and evaluation of two series of 4'-aza-carbocyclic nucleosides as adenosine A2A receptor agonists. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1219-24. | ||||
REF 45 | Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine r... Eur J Med Chem. 2010 May;45(5):1739-45. | ||||
REF 46 | Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700. | ||||
REF 47 | 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. | ||||
REF 48 | Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. | ||||
REF 49 | Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. | ||||
REF 50 | 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem. 1985 Apr;28(4):487-92. | ||||
REF 51 | Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. | ||||
REF 52 | Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83. | ||||
REF 53 | Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. | ||||
REF 54 | Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3. | ||||
REF 55 | Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem. 1997 Aug 1;40(16):2588-95. | ||||
REF 56 | Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp. J Nat Prod. 1998 Feb;61(2):301-5. | ||||
REF 57 | Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A... J Med Chem. 1998 Jun 4;41(12):2126-33. | ||||
REF 58 | Medicinal chemistry of A2A adenosine receptor antagonists. Curr Top Med Chem. 2003;3(4):403-11. | ||||
REF 59 | Caffeine inhibition of rat carotid body chemoreceptors is mediated by A2A and A2B adenosine receptors. J Neurochem. 2006 Jul;98(2):616-28. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.